Status:
COMPLETED
Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer
Lead Sponsor:
Fudan University
Conditions:
Unresectable Liver Metastasis of Colorectal Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate whether TAC plus FOLFOX4 are able to improve resection rate and overall survival in patients receiving primary colorectal tumor resection than given FOLFOX4...
Detailed Description
We administered three cycles FOLFOX4 plus on TAC (oxaliplatin, FUDR and MMC) or FOLFOX4 only to primary colorectal tumor resected patients with unresected liver metastasis. The study endpoints were re...
Eligibility Criteria
Inclusion
- age \< 75 years with histologically proven adenocarcinoma of the colon or rectum
- no severe major organ dysfunction
- WHO performance status of 0 or 1
- no prior cancer therapy
- with measurable unresectableliver metastasis
- without other metastasis
Exclusion
- age \>= 75
- severe major organ dysfunction
- WHO performance status of \>1
- prior cancer therapy
- with other metastasis
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00869271
Start Date
January 1 2005
End Date
December 1 2007
Last Update
March 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032